<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03039621</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-ER-009</org_study_id>
    <nct_id>NCT03039621</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children</brief_title>
  <official_title>International Multicenter Double-blind Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain additional data on efficacy and safety of Ergoferon in
      the treatment of acute respiratory viral infections in children aged from 6 months to 6
      years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to the alleviation of all symptoms of the acute respiratory viral infection based on patient diary data</measure>
    <time_frame>From the time of randomization until the time of alleviation of all symptoms, assessed up to 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to a normal body temperature</measure>
    <time_frame>From the time of randomization until the time of normal body temperature, assessed up to 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the alleviation of general/non-specific symptoms</measure>
    <time_frame>From the time of randomization until the time of absence of general/non-specific symptoms, assessed up to 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the alleviation of nasal/throat/chest symptoms</measure>
    <time_frame>From the time of randomization until the time of absence of nasal/throat/chest symptoms, assessed up to 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total severity scores of disease based on patient diary data</measure>
    <time_frame>Study entry, Days 2-6</time_frame>
    <description>based on patient diary data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of acute respiratory viral infection based on patient diary data</measure>
    <time_frame>Study entry, Days 1-6</time_frame>
    <description>area under the curve for the total severity scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with recovery based on patient diary data</measure>
    <time_frame>Study entry, Days 1-6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of antipyretic use (for prescribed indications) based on patient diary data</measure>
    <time_frame>Study entry, Days 1-6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with complications of acute respiratory viral infection, including those requiring antibiotic administration or hospitalization)</measure>
    <time_frame>From the time of randomization up to 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Acute Respiratory Viral Infections</condition>
  <arm_group>
    <arm_group_label>Ergoferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet 3 times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet 3 times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergoferon</intervention_name>
    <arm_group_label>Ergoferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of both sexes aged from 6 months to 6 years old .

          2. Diagnosis of acute respiratory viral infection based on physician examination: oral
             temperature of at least 38.0°C at examination + total symptom severity score ≥5.

          3. The first 24 hours from the beginning of manifestations of acute respiratory viral
             infection .

          4. Patients presenting during a seasonal morbidity raise of acute respiratory viral
             infection.

          5. Availability of a patient information sheet (Informed Consent form) signed by the
             patient's parents/adopters to confirm the child's participation in the clinical trial
             signed by one parent/adopter of patient.

        Exclusion Criteria:

          1. Suspected pneumonia or bacterial infection (e.g. meningitis, sepsis, otitis media,
             urinary tract infection, etc.) requiring antibacterial therapy starting from Day 1 of
             the illness onset.

          2. Suspected initial manifestations of diseases that have symptoms similar to ARVI (other
             infectious diseases, influenza-like syndrome at the onset of Autoimmune Disorders of
             Connective Tissue, oncohematology and other pathology).

          3. Clinical symptoms of severe influenza infection/ARVI requiring hospitalization.

          4. Medical history or prior diagnosis of primary and secondary immunodeficient disease;
             oncology disease.

          5. Exacerbation or decompensation of a chronic disease (diabetes mellitus, infantile
             cerebral palsy, mucoviscidosis/cystic fibrosis, primary ciliary dyskinesia,
             bronchopulmonary dysplasia, сongenital malformations of the respiratory system and
             ETN, etc.) that would affect the patient's ability to participate in the clinical
             trial.

          6. Malabsorption syndrome, including congenital or acquired lactose intolerance/lactase
             deficiency or any other disaccharidase deficiency and galactosemia.

          7. Allergy/ intolerance to any of the components of medications used in the treatment.

          8. Course intake of medicines listed in the section &quot;Prohibited concomitant treatment&quot;
             for 2 weeks prior to the enrollment in the trial.

          9. Subjects whose parents/adopters, from the investigator's point of view, will fail to
             comply with the observation requirements of the trial or with the intake regimen of
             the investigated medicines.

         10. Participation in other clinical trials within 3 months prior to the enrollment in this
             study.

         11. Patient's parents/adopters are related to the research staff of the clinical
             investigative site who are directly involved in the trial or are the immediate family
             member of the researcher. The immediate family members include husband/wife, parents,
             children or brothers (or sisters), regardless of whether they are natural or adopted.

         12. The patient's parent/adopter works for OOO &quot;NPF &quot;MATERIA MEDICA HOLDING&quot; (i.e., is the
             company's employee, temporary contract worker or appointed official responsible for
             carrying out the research) or the immediate relative.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mikhail Putilovskiy, MD</last_name>
    <phone>+74952761571</phone>
    <phone_ext>302</phone_ext>
    <email>PutilovskiyMA@materiamedica.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kazakh Medical Continuing Education University</name>
      <address>
        <city>Almaty</city>
        <zip>050057</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Kazakh National Medical University named after S.D. Asfendiyarov</name>
      <address>
        <city>Almaty</city>
        <zip>081100</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tatyana Imambayeva, MD, PhD, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Tatyana Imambayeva, MD, PhD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Astana Medical University</name>
      <address>
        <city>Astana</city>
        <zip>010000</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Karaganda State Medical University</name>
      <address>
        <city>Karaganda</city>
        <zip>100000</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karlygash Alikhanova, MD, PhD, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Karlygash Alikhanova, MD, PhD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Kazan Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Kazan'</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ildar Nurmeev, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ildar Nurmeev, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Pirogov Russian National Research Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Pirogov Russian National Research Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Korolev</last_name>
    </contact>
    <investigator>
      <last_name>Alexander Korolev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;Diagnostics and Vaccines&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>129515</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Health Care Institution &quot;Сity Polyclinic №44&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>192071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>State Educational Establishment of Higher Professional Training Nizhny Novgorod State Medical Academy of the Ministry of Public Health of the Russian Federation</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Viktor Krasnov, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Viktor Krasnov, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Municipal Health Care Institution &quot;City Child Health Clinical Polyclinic №5&quot;</name>
      <address>
        <city>Perm'</city>
        <zip>614066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institutionof Higher Education &quot;Yaroslavl State Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Yaroslavl'</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataliya Chernaya, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Nataliya Chernaya, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institutionof Higher Education &quot;Yaroslavl State Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Yaroslavl'</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2016</study_first_submitted>
  <study_first_submitted_qc>January 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2017</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

